𝔖 Bobbio Scriptorium

✦ LIBER ✦

Abstract No. 75: Focal Therapy for Prostate Cancer-120 Patients with Up to 12 Year Follow-Up

✍ Scribed by Onik, G.

Book ID: 122501398
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 108 KB
Volume: 20
Category: Article
ISSN: 1051-0443
DOI: 10.1016/j.jvir.2008.12.064

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The “male lumpectomy”: Focal therapy for

The “male lumpectomy”: Focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up

✍ Gary Onik; David Vaughan; Richard Lotenfoe; Martin Dineen; Jeff Brady 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 96 KB

A ten year follow-up of 682 patients tre

A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States

✍ G.E. Hanks; J.J. Diamond; J.M. Krall; K.L. Martz; S. Kramer 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 743 KB

Differences in Time to Disease Progressi

Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12Years of Follow-up

✍ Kibel, A.S. 📂 Article 📅 2014 🏛 Elsevier Science ⚖ 46 KB

Adjuvant chemo-hormonal therapy with cyc

Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate (MPA) for node-positive cancer patients, update at 12 years follow up

✍ P.S.G.J. Hupperets; J.A.J.M. Wils; L. Volovics; L.J. Schouten; M.M.F. Fickers; H 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 142 KB

PS2 Late breaking Adding bicalutamide 15

PS2 Late breaking Adding bicalutamide 150mg to standard care for localised or locally advanced prostate cancer: results from the largest hormonal therapy trial ever conducted in prostate cancer patients, at over 7 years' follow up

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Adding arabinosylcytosine to idarubicin

Adding arabinosylcytosine to idarubicin induction therapy may not improve survival for people with newly diagnosed acute promyelocytic leukaemia: Abstracted from: Avvisati G, Petti M, Lo-Coco F et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study. LAP 0389 with 7 years of minimal follow-up. Blood 2002; 100 (9): 3141–6.

✍ Elihu Estey; Miguel A. Sanz 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 77 KB